Ipratropium: Side Effects, Uses & Monitoring
Ipratropium Bromide Inhalation Solution administered either alone or with other bronchodilators, especially beta adrenergics, is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chr
- Data source
- FDA labeling via NIH DailyMed (label 7159cf05…)
- Label version
- current
- Last reviewed
- 2026
Reported adverse reactions
Reactions listed in current FDA labeling, with the highest frequency reported across summarized placebo-controlled trials.
| Adverse reaction (as reported in labeling) | Reported frequency* |
|---|---|
| Bronchitis | 24.5% |
| Dyspnea | 16.7% |
| Upper respiratory tract infection | 16% |
| Headache | 9% |
| Tremor | 8.3% |
| Coughing | 8% |
| Influenza-like symptoms | 6.5% |
| Nervousness | 6.5% |
| Respiratory disorder | 6.5% |
| Chest pain | 5.6% |
| Pharyngitis | 5.6% |
| Bronchospasm | 5.4% |
| Sinusitus | 5.4% |
| Pain | 5% |
| Insomnia | 4.6% |
| Sputum increased | 4.6% |
| Rhinitis | 4.2% |
| Nausea | 4.1% |
| Hypertension/hypertension aggravated | 4% |
| Dizziness | 4% |
*Highest percentage reported for the active moiety across placebo-controlled trial tables in current FDA labeling. Values reflect trial reporting, not your individual risk.
Labeled uses (from FDA prescribing information)
Ipratropium Bromide Inhalation Solution administered either alone or with other bronchodilators, especially beta adrenergics, is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.
Conditions associated with Ipratropium in labeling
Frequently Asked Questions
What is Ipratropium used for?
FDA labeling lists the approved uses shown above under "Labeled uses." This summary is informational; only a qualified prescriber can determine whether a medication is appropriate for you.
What are the most commonly reported side effects of Ipratropium?
The table above shows adverse reactions and the highest frequencies reported in placebo-controlled trials summarized in current FDA labeling for Ipratropium. Individual risk varies.
Does Ipratropium require lab monitoring?
Monitoring needs vary. Ask your healthcare provider whether any lab tests apply while taking Ipratropium.
Where does this information come from?
All clinical facts on this page were extracted from the current FDA-registered product labeling for this ingredient, published by manufacturers through NIH DailyMed. See the source link below.
Medical disclaimer: Educational content extracted from public FDA labeling. Not medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.